1. Scrip
  2. >>Business
  3. >>Financing

AM-Pharma Raises €116m To Finance Solo Phase III Trial

 
• By Mike Ward

Following Pfizer’s decision not to take up an option to acquire the Dutch company, AM-Pharma has returned to the venture capital market to get backing for a single pivotal Phase III trial of reCAP in acute kidney injury.

Euro currency
AM-Pharma Concludes Largest Fundraising To Date

AM-Pharma BV has persuaded a syndicate of established European venture capitalists, co-led by new investors LSP and Andera Partners, to back a multinational pivotal Phase III trial of its recombinant alkaline phosphatase (reCAP) to treat acute kidney injury (AKI). The Bunnick, the Netherlands-based biotech has raised €116m ($133m) and is now going it alone after it was told, at the end of the second quarter 2018, that Pfizer Inc. would not be exercising an acquisition option secured as part of a 2015 deal.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.